Affibody reports progress on molecular imaging

02/11/2008 |

Swedish molecular-imaging company Affibody Holding AB saw an increase in revenue in 2007 and reported progress on molecules for molecular imaging. "We focused our resources on our second-generation Affibody molecules and are on track to commence the first clinical study with our lead cancer imaging product ABY-025 in mid-2008," the company's CEO said in a news release.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care